rss rss rss rss rss OncoVista Innovative Therapies   OTC BB: OVIT
Home | Contact Us | 210.677.6000
Our People

Management Team






Alexander L. Weis, PhD
Chairman, CEO & President

Co-founder of ILEX Oncology.
Founder of Lipitek, worked with Vector Therapeutics, Sterling Winthrop, Weizmann Institute, CTRC.
Fellow of the Royal Society of Chemistry.
South Texas Entrepreneur of the Year in 1996.
20+ years in bio-pharmaceutical industry; over 60 publications and 28 patents.
[ top of page ]



Clinical Advisory Board


Eric Rowinsky, MD (Chairman of the SAB)

Senior VP and Chief Medical Officer at ImClone Systems, Inc.
Key role in development of: Taxol® and Hycamtin®.
[ top of page ]

Esteban Cvitkovic, MD

Key role in development of: Eloxatin™, Taxotere® and Camptosar®
[ top of page ]

Ronald P. McCaffrey, MD

Harvard Medical School
Massachusetts General Hospital
[ top of page ]

Pedro Santabarbara, MD, PhD

VP Strategic Development and Medical Affairs at PHARMA MAR S.A.
Key role in development of: Taxol®;, Taxotere®, Campath®; and Tarceva®.
[ top of page ]

Allan M. Green, MD, PhD, JD

Expert in FDA regulatory matters and business strategy
Advisor to pharmaceutical industry
[ top of page ]

 

Investor Resources

img

Investor Information Brief
Adobe PDF Format, ~1.4MB
Opens in a New Browser Window

SEC Filings

Section 16 (Insider) Filings
Opens in a New Browser Window

Alex Weis - Steve Crowley interview

Opens in a new browser

Alex Weis - Jordan Kimmel interview

Opens in a new browser

contact

OncoVista is dedicated to providing safe, innovative and efficacious treatments for cancer.
Follow the links below or contact us to learn more about our industry-leading products, technologies and people.

Our Products.